Jeremy caught up with Sarah 'The Moderatrix' Lowther on our recent news:

✅ Exclusive Option Agreement to Acquire Orphan Drug Candidate
🤝 Appointment of Joint Broker
☑️ Significant POLB 001 Patent Granted in the US

Tune in:
youtube.com/watch?v=lCxgzx…

#POLB $POLBF

Jeremy was delighted to have connected with so many new & existing investors at yesterday's MelloEventsUK in London.

Thank you to everyone who joined our presentations & we look forward to connecting with you again soon 🚀

#POLB $POLBF #Mello24 #London

Our latest deck is available to download ⬇️ on our website.

Click on the link below to download our latest deck, watch our most recent presentations & see our upcoming events:

poolbegpharma.com/investors/even…

#POLB #CompanyPresentation $POLBF

Our CEO presents our latest Company presentation on DirectorsTalk:

🔬Revenue focussed business model
🎯High value programmes for partnering
🙌 Industry leading team
💪 Robust financial position

Watch here:
directorstalkinterviews.com/poolbeg-pharma…

#POLB #CompanyPresentation #DirectorsTalk

Shining a light on #InternationalBehçetsAwareness Day.

🔍Rare inflammatory immune disease with no cure
🩺 Lifelong symptoms
👩‍⚕️ Impact on patients

Spread the word to help raise awareness on this debilitating disease.

Learn more: behcetsuk.org/about-behcets/

#POLB

Reminder🚨we will be presenting at MelloEventsUK on Wednesday 22 May in Chiswick, London.

Join us to learn more about how #POLB is positioned to generate value for shareholders, while addressing significant unmet medical needs.

Register:
melloevents.com/mello2024/

$POLBF

We are attending the upcoming I Am Biotech BIO International Convention.

With over 20,000 industry leaders from across the globe attending, we look forward to connecting with potential partners at #BIO24

Meet us there:
convention.bio.org/partner

#POLB $POLBF

We will be presenting at this year's MelloEventsUK 2024 in-person event on 22 May in #London .

Join us to learn more about how #POLB is positioned to generate value for shareholders, while addressing significant unmet medical needs.

Register to attend:
melloevents.com/mello2024/

Did you know the orphan drug market is expected to grow more than twice as fast as the non-orphan market?

📈 Expected to grow from US$170bn in 2023 to US$368bn by 2030 (11.6% CAGR)

💊 Orphan drug sales set to account for 20% of all prescription drug sales by 2026

#POLB $POLBF

🌎>7,000 rare diseases

⚕️>300m people living with a #raredisease

💊 Due to low prevalence, diagnosis can be difficult & treatments are often unavailable/inadequate

🎯 Urgent need for scientific research to find solutions & provide support to patients

eurordis.org/information-su…

There's no definitive test to diagnose Behçet's disease. Several tests can check for signs of the condition:

💉Blood tests
💧Urine tests
🩺Scans (X-rays, CT, MRI)
🔪Skin biopsy
☑️ Pathergy test

Other potential causes also need to be ruled out before the diagnosis is made

#POLB

People suffering from #Behçetsdisease can have different #symptoms , however the most common symptom is severe ulcers in the mouth

Slide along to understand the different types of symptoms caused by this rare disease.

⚠️Warning: graphic medical photos

#POLB $POLBF

Want to know more about #Behçet ’s disease?

Genetic Alliance UK have shared a patients story, providing an overview on the severity of this rare disease, highlighting the importance of the need for a cure and effective treatments.

youtube.com/watch?v=AxsfOt…

#Behçet sDisease #POLB $POLBF

Last week Scrip, Citeline Commercial covered the option #POLB signed for an orphan drug candidate for #Behçets Disease.

Read it here:

scrip.citeline.com/SC150193/Deal-…

#raredisease #orphandisease #pharma

Did you see #POLB in UK Investor Magazine ?

🚀 'Poolbeg Pharma shares jump after announcing year of progress'
💪 >$10bn market opportunity for POLB 001
🤝 Option agreement for rare disease treatment
💰 Robust cash balance

ukinvestormagazine.co.uk/poolbeg-pharma…

#POLB $POLBF

In case you missed Tuesday's Investor Meet Company Company presentation featuring our CEO, CBO and the CEO of Silk Road Therapeutics, you can now catch up with the full recording here:
youtube.com/watch?v=U8CoXk…

#POLB

Our CEO caught up with @VoxMarkets to discuss:

🔦 Operational & financial highlights for 2023
🤝 Rare disease candidate option agreement
🚀 What's to come in 2024

Watch interview:
youtube.com/watch?v=EJxubZ…

#POLB $POLBF #Results

Our Chief Legal Officer spoke with Proactive:

👁️ Granted patent from US Patent Office

🤝 Enhancing the value & attractiveness of #POLB 001 for potential partners

🌱 Why building a strong intellectual property portfolio is so important in pharma

youtube.com/watch?v=zV6BzF…

🎉 We received the fully granted patent from the US Patent Office for our Immunomodulator II patent application.

The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication.

polaris.brighterir.com/public/poolbeg…

#POLB

Our CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK:

🤝 Silk Road Therapeutics option agreement
🦠 Behçet's Disease
🔬 Development of tPTX
🧲 Commercial Attraction
👁️ Overview of #POLB full year results

youtube.com/watch?v=MOTQwb…